Skip to main content
Equibles
DARE logo

DARE · Dare Bioscience, Inc. · Webcasts, Transcripts & Audio

Track DARE — free

Use DARE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DARE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.84 +0.00 (+0.04%) At close · Oct 5
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's current analysis of the conditions described above, there is substantial doubt about the Company's ability to continue as a going concern within the 12 month period from the issuance date of the accompanying condensed consolidated financial statements given that the timing and amount of potential revenue the Company may generate remain uncertain.”
View the 10-Q filed Aug 13, 2026
Market Cap
$13.29M
Shares
15.29M
Volume · Oct 5 157.17K Avg daily vol (3M) 518.23K

Dare Bioscience, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Dare Bioscience, Inc. (DARE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$7.02M '22 Q3 22-11-10 · $ −$8.04M '23 Q1 23-05-11 ▼100% $ −$8.76M '23 Q2 23-08-10 · $1.00M −$8.30M '23 Q3 23-11-09 · $1.81M −$5.06M '23 Q4 24-03-28 · $9,302 −$6.76M '24 Q1 24-05-14 · $22,438 $12.91M '24 Q2 24-08-12 ▼95.8% $41,691 −$4.70M '24 Q3 24-11-14 ▼103.5% $ −$5.51M '24 Q4 25-03-31 ▲173.3% $25,427 −$4.38M '25 Q1 25-05-13 ▼94.6% $2,262 −$3.56M '25 Q3 25-11-17 ▲499.6% $152,455 −$3.00M '26 Q1 26-05-14 LATEST · $187,546 −$2.98M '26 Q2 26-08-13
Earnings call
FY26 · Q2
2026-08-13
Dare Bioscience, Inc. (DARE) Q2 2026 Earnings Call Transcript
Confident tone Dare to Reclaim hormone therapy Financial performance Dare to Play Sildenafil Cream
Revenue
$187,546
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Dare Bioscience, Inc. (DARE) Q1 2026 Earnings Call Transcript
Positive tone DARE to PLAY commercial launch and provider uptake Ovaprene Phase 3 trial and contraceptive pipeline Flora Sync LF5 consumer health launch
Revenue
$152,455
▲ 499.6% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Dare Bioscience, Inc. (DARE) Q4 2025 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-17
Dare Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript
Confident tone DARE to PLAY Sildenafil Cream Commercial Launch via 503B Women's Health Mission and Positioning Grant-Funded Clinical Pipeline
Revenue
$2,262
▼ 94.6% YoY
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Dare Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript
Confident tone DARE to PLAY Sildenafil cream commercial launch Ovaprene Phase III contraceptive trial Dual-path commercialization strategy
Diluted EPS
$-0.45
▼ 129.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Dare Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript
Confident tone Ovaprene Phase 3 / contraceptive Monthly hormone therapy (DARE-HRT1) Sildenafil Cream commercialization
Revenue
$25,427
▲ 173.3% YoY
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Dare Bioscience, Inc. (DARE) Q4 2024 Earnings Call
Revenue
$*
▼ 103.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Dare Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript
Confident tone Sildenafil Cream 3.6% for female sexual arousal disorder DARE-PTB1 and DARE-VVA1 early-stage programs Ovaprene Phase III contraceptive study
Revenue
$41,691
▼ 95.8% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Dare Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript
Positive tone Sildenafil Cream Phase 3 readiness Ovaprene contraceptive FDA interactions and regulatory risk
Revenue
$22,438
Diluted EPS
$1.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Dare Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript
Confident tone Sildenafil Cream Phase III for FSAD FDA regulatory interactions Ovaprene Phase III contraceptive
Revenue
$9,302
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-28
Dare Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
Confident tone Ovaprene Phase 3 contraceptive XACIATO commercial launch with Organon Sildenafil Cream for FSAD
Revenue
$1.81M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Dare Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript
Revenue
$1.00M
Diluted EPS
$-1.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Dare Bioscience, Inc. (DARE) Q2 2023 Earnings Call Transcript
Revenue
$
▼ 100% YoY
Diluted EPS
$-1.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Dare Bioscience, Inc. (DARE) Q1 2023 Earnings Call Transcript
Revenue
$
Diluted EPS
$-1.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Dare Bioscience, Inc. (DARE) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Call Transcript
Revenue
$
Diluted EPS
$-0.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-09-01
Dare Bioscience, Inc. (DARE) Q2 2022 Earnings Call Transcript
Revenue
$10.00M
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Dare Bioscience, Inc. (DARE) Q1 2022 Earnings Call Transcript
Diluted EPS
$-1.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Dare Bioscience, Inc. (DARE) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Dare Bioscience, Inc. (DARE) Q3 2021 Earnings Call Transcript
Revenue
$
Diluted EPS
$-2.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Dare Bioscience, Inc. (DARE) Q2 2021 Earnings Call Transcript
Revenue
$
▼ 100% YoY
Diluted EPS
$-2.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Dare Bioscience, Inc. (DARE) Q1 2021 Earnings Call Transcript
Diluted EPS
$-1.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Dare Bioscience, Inc. (DARE) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Dare Bioscience, Inc. (DARE) Q3 2020 Earnings Call Transcript
Diluted EPS
$-2.88
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Dare Bioscience, Inc. (DARE) Q2 2020 Earnings Call Transcript
Revenue
$731,000
Diluted EPS
$-3.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Dare Bioscience, Inc. (DARE) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 webcasts
Key facts CIK 1401914 CUSIP 23666P200 13F (30d) 1 filings 1 filers Visit website Investor relations